Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Cash (2020 - 2025)

Silence Therapeutics' Change in Cash history spans 6 years, with the latest figure at -$70.6 million for Q4 2025.

  • On a quarterly basis, Change in Cash fell 283.22% to -$70.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$110.2 million, a 308.24% decrease, with the full-year FY2025 number at -$110.2 million, down 310.07% from a year prior.
  • Change in Cash hit -$70.6 million in Q4 2025 for Silence Therapeutics, down from $40.4 million in the prior quarter.
  • Over the last five years, Change in Cash for SLN hit a ceiling of $74.0 million in Q1 2024 and a floor of -$70.6 million in Q4 2025.
  • Historically, Change in Cash has averaged -$744570.2 across 5 years, with a median of -$3.1 million in 2024.
  • The widest YoY moves for Change in Cash: up 16706.5% in 2022, down 1253.11% in 2022.
  • Tracing SLN's Change in Cash over 5 years: stood at $3.0 million in 2021, then crashed by 1253.11% to -$34.9 million in 2022, then surged by 94.44% to -$1.9 million in 2023, then soared by 2085.72% to $38.5 million in 2024, then tumbled by 283.22% to -$70.6 million in 2025.
  • Business Quant data shows Change in Cash for SLN at -$70.6 million in Q4 2025, $40.4 million in Q3 2025, and -$23.3 million in Q2 2025.